Rhinomed confirmed that it will launch its revolutionary new ProntoTM rechargeable, dual action, vapour release technology in the second half of 2019 following the receipt of initial purchase orders from one of the USA's leading drug store chains. Revolutionary new ProntoTM technology suite: Based on the company's existing BreatheAssistTM stenting technology ­ which has successfully seen the release of two variants MuteTM and TurbineTM ­ the new ProntoTM range includes the novel AirstreamTM release system that allows a specific amount of a formulation to be released into the nasal airstream over a set period of time. By combining this new vapour release technology with the Mute's stenting action, Rhinomed provides users with a unique dual action medical device that not only improves nasal airflow, but also delivers the associated benefits of the specific formulation. This unique and patented technology has a broad range of applications and can be tailored to suit specific formulations of drugs, while also being tailored to suit specific drug delivery profiles for example - low dose, long release, or high dose, fast acting. Rhinomed has also developed a novel rechargeable system that recharges the device allowing it to be reused a set number of times ­always releasing a set amount of the formulation upon recharge. Pronto roll out initially in USA: Following the completion of the product development program and initial consumer testing in 2018 and early 2019, the company presented the new ProntoTM technology range in prototype form to retailers at the recent ECRM Drug Store and Grocery sales show held in Chicago in early February 2019. As a result of the positive reaction from retailers to both products the company began tooling and has commenced production with its China based production partner. Rhinomed can confirm that it has now received an initial purchase order for the ProntoTM Sleep Aid product. Rhinomed will ship product at the end of May and expects to see Pronto Sleep on shelf by August/September. The Pronto Clear Nasal decongestant product - targeting nasal congestion, cough, cold and allergy issues ­ which had global retail value sales topping USD 34 billion in 2014 ­will be released later in 2019 in time for the North American cough, cold, flu season. Rhinomed can confirm that both Pronto products will initially be sold online and through select retail partners. An initial focus will be on the US market and the company anticipates that it will receive rolling notification of other stockists and stocking levels for both the ProntoTM Sleep Aid and the ProntoTM Clear Decongestant products over the coming months and will update investors as purchase orders are received.